Axial spondyloarthritis (axSpA) is a disease concept entailing the disease entities ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).

According to the modified New York criteria, radiographic signs of sacroileitis are mandatory whilst nr-axSpA lack these and is instead, according to the ASAS classification criteria, classified based on imaging with MRI of the sacroiliac joints and/or based on a combination of HLA-B27 positivity in combination with clinical parameters.

However, both AS och nr-axSpA have an equal burden of disease. Patients with nraxSpA failing conventional treatment with at least 2 different NSAIDs and concomitantly having high disease activity are according to EULAR guidelines eligible for biologic treatment. Besides TNF-inhibition, also IL17-inhibition is now indicated for treatment of nraxSpA.

Novartis invites you to a streamed lecture with Lennart Jacobsson, Sr Professor Rheumatology at Sahlgrenska academy, Gothenburg, Sweden and Doctor Giovanni Cagnotto, Skane University Hospital, Malmö, Sweden who was a principal investigator in the PREVENT study, will give a lecture on nr-axSpA and the results from the PREVENT study, studying the efficacy and safety of IL-17A inhibitor, secukinumab in patients with nr-axSpA.

Sr professor Lennart Jacobsson, Sahlgrenska Academy
Dr Giovanni Cagnotto, Skane University Hospital

Thursday September 17th at 16:00-17:00 CET

Webstreaming from film studio in Malmö.

  • Participation in the meeting requires approval from the head of department.
  • Participation in the meeting is free of costs.
Thomas Mandl, Medical Advisor
Non-radiographic axial SpA overview
Lennart Jacobsson, Sahlgrenska Academy
PREVENT study – Secukinumab in nraxSpA
Giovanni Cagnotto Skane University Hospital
Questions and answers
Lennart Jacobsson and Giovanni Cagnotto
SE2006171986 (17 juni 2020)

Medical Information Request


Ask Speakers

Anmälan 17 september

Genom att anmäla dig till mötet accepterar du att vi behandlar dina uppgifter i enlighet med vår integritetsskyddspolicy.